Amsterdam: Europe’s medicines safety committee has gone back to a question it thought it had answered thirteen years ago. On 4 September the Pharmacovigilance Risk Assessment Committee opened a review of injectable iron-containing medicines, covering every formulation rather than the single product that generated most of the case reports, and the trigger is hypophosphataemia and the bone damage that can follow it.
Low blood phosphate is not an obscure side effect. Regulators classify it as common for ferric carboxymaltose, meaning up to one patient in ten, and prolonged depletion can cause osteomalacia, a softening of bone that presents as fracture or persistent pain. Clinicians who treat anaemia in inflammatory bowel disease, heavy menstrual bleeding or chronic kidney failure have argued for several years that the monitoring advice attached to these products does not match how the drugs are actually used.
That gap between labelling and practice is the committee’s real subject. Intravenous iron moved out of hospitals into day units and infusion clinics, repeat courses became routine, and phosphate testing between courses did not become routine alongside them. Existing risk minimisation measures assume a prescriber who checks. The review asks whether that assumption survives contact with a busy service.
Widening the scope to all injectable iron changes the commercial stakes considerably. Iron sucrose, ferric derisomaltose and iron isomaltoside are marketed by different companies and carry different reported rates, so a class-wide conclusion would land on manufacturers who regard their own products as the safer option. Each will now file data arguing precisely that, and the committee will have to decide whether the differences are real or an artefact of how each product is reported and used.
The procedural weight here is worth noting. A review of this kind ends in a recommendation on the benefit-risk balance, and the committee can ask for mandatory phosphate monitoring, revised prescribing information, direct communications to healthcare professionals, or restrictions on repeat dosing. It can also conclude that the current wording is adequate. The committee’s remit gives it no power to act on cost, only on safety.
Haematologists will resist anything that makes intravenous iron harder to give. Oral iron fails or is poorly tolerated in a substantial share of patients, and the alternative to an infusion is often a transfusion, which carries risks of its own and consumes a scarcer resource. Any restriction therefore has to be weighed against what replaces it, and patient groups have already made that argument in writing.
Reviews of this scale run for months rather than weeks, and the meeting highlights give no completion date. Prescribers face the interval with unchanged labelling and a published doubt, which is an uncomfortable place to treat an anaemic patient who needs iron this week.
